Attenuated Technologies

We build biotech companies.

Michael Churchill, Ph.D. — Biotechnology Executive, Company Builder & Scientific Founder

Michael works at the intersection of science, strategy, technology, and execution—building the organizations, products, and clinical programs required to translate scientific innovation into meaningful impact.

Attenuated Technologies is his independent biotechnology operating practice for selected executive appointments, strategic engagements, and company-building work.

View Experience About Michael Explore the Practice

Biotechnology company formation and platform strategy

Precision medicine and commercialization

Translational strategy and first-in-human execution

Cross-functional leadership and strategic operations

Company-Building Experience

Selected experience across precision diagnostics, synthetic biology, clinical-stage therapeutics, and biotechnology commercialization.

MultiOmics

MultiOmics is an AI-native precision-diagnostics company focused on early breast-cancer detection.

Michael's role: Interim CSO/CBO through Attenuated Technologies. Michael leads scientific development, operating coordination, corporate strategy, business-development support, and AI strategy.
Outcome: Selected for the 2025 C10/LabCentral AI-BioHub cohort. Michael created the application and pitch materials used during the program.

View Engagement

Brahma Therapeutics

Brahma Therapeutics was formed around a de novo peptide-engineering platform and the opportunity to translate foundational academic technologies into a biotechnology company.

Michael's role: Founder & Chief Scientist. Michael negotiated foundational licenses, defined the platform and development strategy, and built the scientific operation from concept through proof of concept.
Outcome: Brahma was positioned for and reached a strategic acquisition outcome in May 2023.

View Engagement

CREATE Medicines / Myeloid Therapeutics

CREATE Medicines, formerly Myeloid Therapeutics, is a clinical-stage biotechnology company advancing in vivo CAR programs through first-in-human development.

Michael's role: Senior Director, Translational Science. Michael led biomarker strategy and translational execution for MT302 and directed cross-functional startup of multinational Phase I program MT303.
Outcome: Michael's translational work supported full enrollment of MT302 in under 12 months. MT303 expanded the clinical pipeline and international operating footprint.

View Engagement

SEngine Precision Medicine

SEngine developed a functional precision-oncology platform intended to move from assay development into a CLIA-certified clinical diagnostic service.

Michael's role: Lead Scientist, then Principal Scientist. Michael built the CLIA-certified P.A.R.I.S. test and later supported its physician-facing clinical implementation and broader company development.
Outcome: Michael developed personalized drug panels for more than 100 cancer patients and supported an approximately $9 million financing through financial analysis, valuation work, diligence materials, and company presentations. The CEO led the financing.

View Engagement

Building organizations is part of building the science.

The practice is grounded in clarity, capable teams, intellectual honesty, cross-functional integration, and practical use of artificial intelligence.

Scientific Leadership

Leading with scientific rigor while keeping the path to practical impact in view.

AI-Native Organizations

Designing organizations where AI strengthens how teams learn, decide, and execute.

Company Building

Creating organizations around a clear problem, shared mission, and durable operating systems.

Read Leadership Philosophy

Operating Practice

Executive operating work grounded in company building.

Attenuated Technologies provides continuity across selected executive appointments, strategic engagements, company formation, translational strategy, and future advisory opportunities.

Explore the Operating Practice

Current Areas of Work

Company building
Precision medicine
Translational strategy
Executive operations
Commercialization
AI-enabled workflows

Insights

Published thinking from Michael Churchill on biotechnology, artificial intelligence, scientific leadership, translational medicine, and company building.

Essays in development.

Explore Insights

Build the next biotechnology company.

Michael welcomes conversations about executive appointments, selected strategic engagements, company-building opportunities, and future advisory roles.

Contact Michael View CV